A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers
NCT01578928
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Renal Impairment
Interventions
DRUG:
SOM230
Sponsor
Novartis Pharmaceuticals